TW200904414A - Method for treating CB2 receptor mediated pain - Google Patents

Method for treating CB2 receptor mediated pain Download PDF

Info

Publication number
TW200904414A
TW200904414A TW097109757A TW97109757A TW200904414A TW 200904414 A TW200904414 A TW 200904414A TW 097109757 A TW097109757 A TW 097109757A TW 97109757 A TW97109757 A TW 97109757A TW 200904414 A TW200904414 A TW 200904414A
Authority
TW
Taiwan
Prior art keywords
group
alkyl
aryl
absent
positions
Prior art date
Application number
TW097109757A
Other languages
English (en)
Chinese (zh)
Inventor
Christopher M Flores
Mark J Macielag
Kevin Paul Pavlick
Mingde Xia
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200904414(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of TW200904414A publication Critical patent/TW200904414A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW097109757A 2007-03-21 2008-03-20 Method for treating CB2 receptor mediated pain TW200904414A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89601707P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
TW200904414A true TW200904414A (en) 2009-02-01

Family

ID=39766330

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097109757A TW200904414A (en) 2007-03-21 2008-03-20 Method for treating CB2 receptor mediated pain

Country Status (13)

Country Link
EP (1) EP2139327A4 (nl)
JP (1) JP2010522182A (nl)
KR (1) KR20090120500A (nl)
CN (1) CN101677555A (nl)
AR (1) AR065801A1 (nl)
AU (1) AU2008229265A1 (nl)
CA (1) CA2681384A1 (nl)
CL (1) CL2008000817A1 (nl)
MX (1) MX2009010164A (nl)
PE (1) PE20090551A1 (nl)
TW (1) TW200904414A (nl)
UY (1) UY30974A1 (nl)
WO (1) WO2008115672A1 (nl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090179A2 (en) 2010-12-30 2012-07-05 Lupin Limited Isoquinoline derivatives as cannabinoid receptor modulators
WO2012090177A2 (en) 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
IN2014MN00226A (nl) 2011-07-05 2015-09-25 Lupin Ltd

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060128976A (ko) * 2003-12-29 2006-12-14 세프라코 아이엔시. 피롤 및 피라졸 디에이에이오 억제제
DK1735286T3 (da) * 2004-03-24 2012-04-02 Janssen Pharmaceutica Nv Tetrahydroindazoler som cannabinoidmodulatorer
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
DE602006012514D1 (de) * 2005-09-23 2010-04-08 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl-pyrazol-cannabinoid-modulatoren

Also Published As

Publication number Publication date
UY30974A1 (es) 2008-09-30
CN101677555A (zh) 2010-03-24
MX2009010164A (es) 2009-10-12
CA2681384A1 (en) 2008-09-25
WO2008115672A1 (en) 2008-09-25
EP2139327A4 (en) 2011-06-15
CL2008000817A1 (es) 2008-09-26
PE20090551A1 (es) 2009-05-16
AR065801A1 (es) 2009-07-01
EP2139327A1 (en) 2010-01-06
JP2010522182A (ja) 2010-07-01
KR20090120500A (ko) 2009-11-24
AU2008229265A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
JP5371790B2 (ja) 睡眠および認知に関するうつ病における残存症状の治療のための組み合わされたセロトニン再取り込み、５−ｈｔ３および５−ｈｔ１ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジン
EP1908753B1 (en) Novel heterocyclidene acetamide derivative
KR101785072B1 (ko) 하지 불안 증후군의 치료방법
JPS6075429A (ja) 鎮痛用組成物
JP2009527525A (ja) 尿失禁治療用のベンゾイミダゾロン誘導体
KR19990067698A (ko) 세로토닌 재흡수 억제제의 위장 효과를 극복하기 위한 5ht4수용체 길항제의 용도
JP2010521516A (ja) 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用
TW201002725A (en) Thiazolyl-and oxazolyl-isoquinolinones and methods for using them
NO321606B1 (no) Pyrrolderivater og medisinsk sammensetning
JPH085787B2 (ja) 痴呆及び脳血管障害予防・治療剤並びに血小板凝集抑制剤
TW200904414A (en) Method for treating CB2 receptor mediated pain
JPWO2006064780A1 (ja) 便秘治療剤
JP3939369B2 (ja) β３ −アドレナリン作動薬として作用する｛（７Ｓ）−７−［（２Ｒ）−２−（３−クロロフェニル）−２−ヒドロキシエチルアミノ］−５，６，７，８−テトラヒドロナフタレン−２−イルオキシ）酢酸及びその薬学的に許容されうる塩、並びにそれらが存在する薬学的組成物及び研究室用試薬
CN101720186A (zh) (-)-e-10-oh-nt组合物及其合成与使用的方法
TW200901976A (en) Hexahydro-cycloheptapyrazole cannabinoid modulators
CN105497020A (zh) 胺类化合物的光学异构体治疗疼痛的医药用途
TWI296522B (en) Colonic motor dysfunction remedies comprising aminothiazole derivatives as active ingredients
EP3860996A1 (en) Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
JP2000309545A (ja) 愛玩動物の年齢関連行動障害治療方法および治療用組成物
JP2008504306A (ja) 神経因性疼痛、線維筋痛症または慢性関節リウマチの治療
JP2008106028A (ja) 慢性疼痛の治療におけるフリバンセリンの使用
TW200901972A (en) Method for treating CB2 receptor mediated pain
JP2010536827A (ja) ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体
US20090215850A1 (en) Method for treating cb2 receptor mediated pain
JP2022501315A (ja) 病的炎症の新しい医療